This article is more than 5 years old. Information may no longer be current.

Pfizer licenses human gene thought to cause wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Pfizer Inc. has obtained exclusive worldwide rights from Quark Biotech Inc. for a novel human gene thought to proliferate the pathologic blood vessels, causing exudative age-related macular degeneration, the company announced.

Under the agreement, which awaits Federal Trade Commission approval, Pfizer will also obtain exclusive rights to molecules that modify the gene's expression or function. Preclinical trials suggest that using RNA interference to block the gene, called RTP-801, can successfully treat wet AMD, according to the release.